The notorious oxyquinone manufacturer Purdue Pharma, which has been widely criticized for its misleading marketing of its highly addictive analgesic and its role in accelerating the nationwide epidemic of opioid abuse and overdose deaths, is driving forward a new, effective drug be an antidote to opioid overdoses.
The company announced this week that the US Food and Drug Administration is fast-acting the investigational nalmefene hydrochloride (HCl), an injectable emergency treatment, to rescue people suspected of having an opioid overdose Has. Purdue points out that the effect of nalmefene HCl lasts longer than the similar emergency falloidal antagonist naloxone. Therefore, the company hopes that nalmefene HCl will outperform naloxone in reversing overdoses of the highest potency opioid fentanyl, which is currently causing the alarming deaths from opioid overdoses. The fast status of the FDA accelerates the development and review of the drug.
"Opioid antagonists such as naloxone have played an important role in the emergency treatment of opioid overdose," said John Renger, head of Purdue, Research & Development and Regulatory Affairs. "However, with fentanyl and its more potent analogues on the increase, we are focusing on a potentially more effective and longer-lasting rescue option specifically designed for these overdose situations."
Deaths from The extremely strong fentanyl began to rise nationwide in 201
In the midst of the crisis, Purdue was severely condemned for downplaying the addictiveness of OxyContin and aggressively marketing it in the mid-1990s, earning billions of dollars in revenue. In 2007, the company and three executives found themselves guilty in a federal court for faking doctors, patients and regulators about drug addiction. Since then, Purdue has been affected by lawsuits that blame the company for driving the rise in abuse of opioids and overdoses. The company has vigorously defended itself against the claims, but is now considering opening insolvency proceedings, which could mitigate litigation and judgments.
In this week's statement, Purdue once again advocated involvement in triggering the epidemic, excluding the use of illegal drugs. The president and CEO of Purdue, Craig Landau, simply described the problem as "fentanyl and the number of illegal opioids continue to increase in the United States and are increasingly fueled by overdose of this class of compounds."
Washington Post Landau said he expected that Purdue's efforts to treat opioid overdoses would be criticized and said:
I acknowledge that everything we do criticizes in this regard will, but in the end we will do what we do right. These are good things that could and should have a positive impact on public health and on patients.
According to this assessment, Purdue announced that he does not intend to make money with the new drug. "As part of Purdue's commitment to advance meaningful solutions to address the opioid crisis, the company will work to advance this option with a commitment not to benefit from future sales of this drug."
According to Purdue's internal discussions publicized in a lawsuit by the Commonwealth of Massachusetts, Purdue and members of the affluent Sackler family owned by the company, the company had the cash-draw potential of treatments aimed at redemption , carefully studied The epidemic.
A non-editorial section of the lawsuit describes a secret plan called Project Tango that explored Purdue's expansion into the sale of treatment options. The lawsuit states that Purdue and a member of the Sackler family noted that the millions of people who had become dependent on opioids were an excellent business opportunity. Purdue employees wrote in internal documents cited in the lawsuit: "It's an attractive market. Large unmet need for susceptible, underserved and stigmatized groups of patients suffering from drug abuse, dependence and dependency. "